Biologic Therapies Summit X and Vasculitis 2023

Biologic Therapies Summit X and Vasculitis 2023

returns to in-person learning, bringing together world leaders in immune-based therapies and addressing cutting-edge topics in immunology and rheumatology. The course begins with a full day devoted to vasculitis, including key issues in the differential diagnosis of vasculitis, CNS vasculitis, ANCA-associated vasculitis, and organ-specific issues in vasculitis.

The Biologic Therapies Summit X offers six sessions over two days, and kicks off with a half-day session featuring talks on CAR T-cell therapy, irAEs, precision medicine and the next generation of JAK inhibitors for IMIDs, and advances in complement biology and therapy. We take a deep dive into rheumatoid arthritis, AS, PsA and SpA in the afternoon. Day two addresses infections, COVID-19, co-morbidities with IMIDs, including ILD and cardiovascular risk in immune-mediated diseases, and lupus. We wrap up the Summit with a session devoted to pain management, as we welcome physician, writer, and clinical researcher, Haider Warraich, MD, for an exploration of the social and scientific fundamentals of pain.

• + Include: 45 videos + 35 pdfs, size: 16.1 GB

NEW THIS YEAR! A half-day session devoted to APPs, with updates on biologics for SpA and RA, factors to consider when choosing biologics, infectious complications of biologics, and an immunology lecture focusing on cytokines.

Why Attend?

1. Join for a full-day devoted to hot topics in Vasculitis
2. Hear from internationally renowned experts in the fields of immunology and rheumatology
3. Expand and enhance decision-making skills for appropriate use of biologic therapies in highly complex clinical situations
4. Participate in our APP workshop, included with course registration

By Attending, You Will Be Able To:

• Describe and critically appraise the immunologic mechanisms of action for targeted therapies and targeted synthetic therapies as they apply to efficacy and safety across the spectrum of immune-mediated inflammatory diseases including PsA, SpA, RA, SLE and vasculitis.
• Outline how precision medicine has been used to manage immune-related adverse events.
• Define advances in complement with rheumatic and immunologic diseases.
• Summarize evidence on COVID-19 and vaccinations and their effects on patients with immune-mediated inflammatory diseases, and describe the implications for clinical practice.
• Critically appraise how Long COVID presents in patients with immune-mediated inflammatory diseases.
• Evaluate comorbidities such as cardiovascular risk and complications associated with immune-mediated diseases.
• Define the clinical differences between type 1 and type 2 lupus.

Who Should Attend?

The Summit is directed towards rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, pharmacists, nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and autoinflammatory disorders.

 

+ Topics:

• Course Syllabus.pdf
• May 11 APP Breakout Session Focus on RA, SpA, and Biologics Safety Factors to Consider When Choosing a Biologic.pdf
• May 11 APP Breakout Session Focus on RA, SpA, and Biologics Safety Immunology Talk Cytokines.pdf
• May 11 APP Breakout Session Focus on RA, SpA, and Biologics Safety Infectious Complications of Biologics.pdf
• May 11 APP Breakout Session Focus on RA, SpA, and Biologics Safety Updates on Biologics for SpA and RA.pdf
• May 11 Session I Key Issues in the Differential Diagnosis of Vasculitis Drug-Induced Vasculitis.mp4
• May 11 Session I Key Issues in the Differential Diagnosis of Vasculitis Drug-Induced Vasculitis.pdf
• May 11 Session I Key Issues in the Differential Diagnosis of Vasculitis IgG4 Related Disease.mp4
• May 11 Session I Key Issues in the Differential Diagnosis of Vasculitis IgG4 Related Disease.pdf
• May 11 Session I Key Issues in the Differential Diagnosis of Vasculitis Relapsing Polychondritis.mp4
• May 11 Session I Key Issues in the Differential Diagnosis of Vasculitis Relapsing Polychondritis.pdf
• May 11 Session I Key Issues in the Differential Diagnosis of Vasculitis Vascular Ehlers-Danlos Syndrome.mp4
• May 11 Session I Key Issues in the Differential Diagnosis of Vasculitis Vascular Ehlers-Danlos Syndrome.pdf
• May 11 Session I Key Issues in the Differential Diagnosis of Vasculitis.mp4
• May 11 Session II CNS vasculitis Radiographic investigations in CNS vasculitis.mp4
• May 11 Session II CNS vasculitis Radiographic investigations in CNS vasculitis.pdf
• May 11 Session II CNS vasculitis Update on CNS vasculitis.mp4
• May 11 Session II CNS vasculitis Update on CNS vasculitis.pdf
• May 11 Session II CNS vasculitis.mp4
• May 11 Session III Current issues in ANCA-associated vasculitis Hypogammaglobulinemia in ANCA- associated vasculitis.mp4
• May 11 Session III Current issues in ANCA-associated vasculitis Hypogammaglobulinemia in ANCA- associated vasculitis.pdf
• May 11 Session III Current issues in ANCA-associated vasculitis Introduction to current issues in ANCA-associated vasculitis.mp4
• May 11 Session III Current issues in ANCA-associated vasculitis Introduction to current issues in ANCA-associated vasculitis.pdf
• May 11 Session III Current issues in ANCA-associated vasculitis Use of Rituximab and Avacopan in ANCA-associated vasculitis.mp4
• May 11 Session III Current issues in ANCA-associated vasculitis Use of Rituximab and Avacopan in ANCA-associated vasculitis.pdf
• May 11 Session III Current issues in ANCA-associated vasculitis.mp4
• May 11 Session IV Organ-specific issues in vasculitis Cardiac manifestations in vasculitis.mp4
• May 11 Session IV Organ-specific issues in vasculitis Cardiac manifestations in vasculitis.pdf
• May 11 Session IV Organ-specific issues in vasculitis Eye disease in vasculitis.mp4
• May 11 Session IV Organ-specific issues in vasculitis Eye disease in vasculitis.pdf
• May 11 Session IV Organ-specific issues in vasculitis Pulmonary disease including ILD in vasculitis.mp4
• May 11 Session IV Organ-specific issues in vasculitis Pulmonary disease including ILD in vasculitis.pdf
• May 11 Session IV Organ-specific issues in vasculitis.mp4
• May 12 Session I Basic and Clinical Immunology for the Busy Clinician Advances in complement biology and therapy in rheumatic and immunologic diseases.mp4
• May 12 Session I Basic and Clinical Immunology for the Busy Clinician Advances in complement biology and therapy in rheumatic and immunologic diseases.pdf
• May 12 Session I Basic and Clinical Immunology for the Busy Clinician Immunopathogenesis of adverse events from immunotherapy of cancer (irAEs) and the prospects for targeted therapy.mp4
• May 12 Session I Basic and Clinical Immunology for the Busy Clinician Immunopathogenesis of adverse events from immunotherapy of cancer (irAEs) and the prospects for targeted therapy.pdf
• May 12 Session I Basic and Clinical Immunology for the Busy Clinician Part 1.mp4
• May 12 Session I Basic and Clinical Immunology for the Busy Clinician Part 2.mp4
• May 12 Session I Basic and Clinical Immunology for the Busy Clinician Precision medicine and the next generation of JAK inhibitors for IMIDs.mp4
• May 12 Session I Basic and Clinical Immunology for the Busy Clinician Precision medicine and the next generation of JAK inhibitors for IMIDs.pdf
• May 12 Session I Basic and Clinical Immunology for the Busy Clinician Taming the T-cell and the prospects for CAR T-cell therapy in autoimmune diseases.mp4
• May 12 Session II Rheumatoid Arthritis Can we treat the disease and the patient Advancing RA therapeutics with precision medicine how close are we.mp4
• May 12 Session II Rheumatoid Arthritis Can we treat the disease and the patient Advancing RA therapeutics with precision medicine how close are we.pdf
• May 12 Session II Rheumatoid Arthritis Can we treat the disease and the patient Treating to target in RA – Putting the patient first.mp4
• May 12 Session II Rheumatoid Arthritis Can we treat the disease and the patient Treating to target in RA – Putting the patient first.pdf
• May 12 Session II Rheumatoid Arthritis Can we treat the disease and the patient.mp4
• May 12 Session III Are you treating your patient with AS and PsA effectively Effectiveness and safety of tapering strategies in Axial SpA- highlighting real world evidence.mp4
• May 12 Session III Are you treating your patient with AS and PsA effectively Effectiveness and safety of tapering strategies in Axial SpA- highlighting real world evidence.pdf
• May 12 Session III Are you treating your patient with AS and PsA effectively Part 1.mp4
• May 12 Session III Are you treating your patient with AS and PsA effectively Part 2.mp4
• May 12 Session III Are you treating your patient with AS and PsA effectively PsA- Deep dive from physiology to pathology.mp4
• May 12 Session III Are you treating your patient with AS and PsA effectively Selecting Management Strategies in PsA and SpA.mp4
• May 12 Session III Are you treating your patient with AS and PsA effectively Selecting Management Strategies in PsA and SpA.pdf
• May 13 Session I Infections, COVID-19, Co-Morbidities with IMIDS Current status of COVID vaccinology in the compromised host.mp4
• May 13 Session I Infections, COVID-19, Co-Morbidities with IMIDS Current status of COVID vaccinology in the compromised host.pdf
• May 13 Session I Infections, COVID-19, Co-Morbidities with IMIDS Immunizations in the immunocompromised.mp4
• May 13 Session I Infections, COVID-19, Co-Morbidities with IMIDS Immunizations in the immunocompromised.pdf
• May 13 Session I Infections, COVID-19, Co-Morbidities with IMIDS Long COVID.mp4
• May 13 Session I Infections, COVID-19, Co-Morbidities with IMIDS Long COVID.pdf
• May 13 Session I Infections, COVID-19, Co-Morbidities with IMIDS Optimal management of COVID-19 in the immunocompromised.mp4
• May 13 Session I Infections, COVID-19, Co-Morbidities with IMIDS Optimal management of COVID-19 in the immunocompromised.pdf
• May 13 Session I Infections, COVID-19, Co-Morbidities with IMIDS.mp4
• May 13 Session II Optimizing outcomes in IMIDs- Focus on Co-Morbidities Assessing and treating cardiovascular risk in immunemediated diseases.mp4
• May 13 Session II Optimizing outcomes in IMIDs- Focus on Co-Morbidities Assessing and treating cardiovascular risk in immunemediated diseases.pdf
• May 13 Session II Optimizing outcomes in IMIDs- Focus on Co-Morbidities Clinical approach to IBD in immunemediated diseases.mp4
• May 13 Session II Optimizing outcomes in IMIDs- Focus on Co-Morbidities Clinical approach to IBD in immunemediated diseases.pdf
• May 13 Session II Optimizing outcomes in IMIDs- Focus on Co-Morbidities ILD across IMIDs.mp4
• May 13 Session II Optimizing outcomes in IMIDs- Focus on Co-Morbidities ILD across IMIDs.pdf
• May 13 Session II Optimizing outcomes in IMIDs- Focus on Co-Morbidities.mp4
• May 13 Session III Lupus- Advances in diagnosis and management Advances in biologics in lupus.mp4
• May 13 Session III Lupus- Advances in diagnosis and management Advances in biologics in lupus.pdf
• May 13 Session III Lupus- Advances in diagnosis and management Type 1 versus Type 2 lupus.mp4
• May 13 Session III Lupus- Advances in diagnosis and management Type 1 versus Type 2 lupus.pdf
• May 13 Session III Lupus- Advances in diagnosis and management.mp4
• May 13 Session IV Pain Management Pain recovery- Cleveland Clinic experience.mp4
• May 13 Session IV Pain Management Pain recovery- Cleveland Clinic experience.pdf
• May 13 Session IV Pain Management RJ Fasenmyer Annual Lectureship- Exploring the Social and Scientific Fundamentals of Chronic Pain.mp4
• May 13 Session IV Pain Management RJ Fasenmyer Annual Lectureship- Exploring the Social and Scientific Fundamentals of Chronic Pain.pdf
• May 13 Session IV Pain Management.mp4